ArticleBasic & clinical pharmacology & toxicology2025
Trends in Proton-Pump Inhibitor Use Among Danish Adults: A Nationwide Drug Utilization Study 2015-2023.
Article in Basic & clinical pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global increase in proton-pump inhibitor (PPI) use has raised concerns about their appropriate use, particularly due to potential overprescription and associated adverse effects. This study examines PPI utilization patterns among Danish adults from 2015 to 2023 using the Danish nationwide health registries. We estimated the annual incidence rate (users per 100 person-years) and monthly prevalence (proportion with a filled prescription or sufficient tablets). Treatment duration was assessed using the 'proportion of patients covered' and the Kaplan-Meier method. We also calculated the proportion of adults with concomitant use of ulcerogenic drugs over time. We identified 1 729 440 adults who filled at least one PPI prescription during 2015-2023. The prevalence increased from 7.0% in 2015 to 8.2% in 2023, while incidence rate remained stable at ~3 users per 100 person years. PPI use increased with age. Three years after initiation, 17% used PPIs, while 1.5% had remained on continuous treatment. In 2023, 50% of users had concomitant ulcerogenic drug use, a 3.2% increase since 2015. The prevalence of PPI use in Denmark has risen markedly reaching a high stable level, with a clear age-dependent trend. Increased attention to appropriate PPI use is necessary to ensure rational prescribing and prevent potential overuse.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.